Common Stock, par value $0.0001 per share
- Symbol
- IPSC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
Century Therapeutics, Inc.
IPSCNASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01 Regulation FD Disclosure On October 2, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing that nonclinical data from the Company’s iPSC-derived cell therapy platform was presented at the European Association for the Study of Diabetes (“EASD”) held on October 2, 2026 in Milan, Italy.…
Company context
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
Current securities
Registered securities in this filing
Century Therapeutics, Inc. · 8-K · Filed 2026-10-02
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On October 2, 2026, Century Therapeutics, Inc. (the “Company”)
issued a press release announcing that nonclinical data from the Company’s iPSC-derived cell therapy platform was presented at the
European Association for the Study of Diabetes (“EASD”) held on October 2, 2026 in Milan, Italy. The full text of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 7.01 (including Exhibit 99.1)
is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
A copy of the slides presented by the Company at EASD is filed as Exhibit
99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement
or amend the materials attached hereto as Exhibit 99.2.
Filed exhibits (2)
Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027 PHILADELPHIA, October 2nd, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation of nonclinical data for CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0. Data were presented in an oral presentation at the 62 nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. In a study lasting over eleven months, updated data demonstrated CNTY-813 maintained glycemic control in a diabetic mouse model until CNTY-813’s graft removal. New data further h…
Open exhibit ↗Exhibit 99.2 CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research 2 Disclosures Presenter G. Grant Welstead, PhD Relevant Financial Relationship • Employee, Century Therapeutics Presentation Information • This presentation describes preclinical research related to CNTY - 813, an investigational iPSC - derived islet cell therapy for T1D • The content is intended for scientific and educational discussion • No clinical recommendations will be made 2 3 This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present fa cts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines and the initial safety and efficacy profiles of CNTY - 813 and s tatements regarding our preclinical development programs, including preclinical data, development plans and timelines, are forward …
Open exhibit ↗